Trial Profile
Phase II Trial of the MEK1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 12 Sep 2022
Price :
$35
*
At a glance
- Drugs Selumetinib (Primary)
- Indications Neurofibromatosis 1; Plexiform neurofibroma
- Focus Therapeutic Use
- 26 May 2022 Status changed from recruiting to active, no longer recruiting.
- 26 May 2022 Status changed from recruiting to active, no longer recruiting.
- 02 Oct 2020 Planned End Date changed from 31 Aug 2021 to 1 Jan 2025.